Tertatolol | CAS#83688-84-0 | beta-receptor antagonist

MedKoo Cat#: 461127 | Name: Tertatolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tertatolol is a beta-receptor antagonist. It is used in the treatment of high blood pressure.

Chemical Structure

Tertatolol

CAS#83688-84-0

Theoretical Analysis

MedKoo Cat#: 461127

Name: Tertatolol

CAS#: 83688-84-0

Chemical Formula: C16H25NO2S

Exact Mass: 295.1606

Molecular Weight: 295.44

Elemental Analysis: C, 65.05; H, 8.53; N, 4.74; O, 10.83; S, 10.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Tertatolol; S-2395; S 2395; S2395;

IUPAC/Chemical Name

(R)-1-(tert-butylamino)-3-(thiochroman-8-yloxy)propan-2-ol

InChi Key

HTWFXPCUFWKXOP-CYBMUJFWSA-N

InChi Code

InChI=1S/C16H25NO2S/c1-16(2,3)17-10-13(18)11-19-14-8-4-6-12-7-5-9-20-15(12)14/h4,6,8,13,17-18H,5,7,9-11H2,1-3H3/t13-/m1/s1

SMILES Code

CC(C)(C)NC[C@@H](O)COc1cccc2c1SCCC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 295.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hefnawy MM, Asiri YA, Al-Zoman NZ, Mostafa GA, Aboul-Enein HY. Stereoselective HPLC analysis of tertatolol in rat plasma using macrocyclic antibiotic chiral stationary phase. Chirality. 2011 Apr;23(4):333-8. doi: 10.1002/chir.20923. Epub 2010 Nov 2. PubMed PMID: 21384438. 2: Kirch W, Milferstädt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. Cardiovasc Drugs Ther. 1990 Apr;4(2):487-91. PubMed PMID: 1981019. 3: Vivet P. Overview of clinical safety and efficacy of tertatolol. Cardiology. 1993;83 Suppl 1:41-50. Review. PubMed PMID: 7903214. 4: Jolas T, Haj-Dahmane S, Lanfumey L, Fattaccini CM, Kidd EJ, Adrien J, Gozlan H, Guardiola-Lemaitre B, Hamon M. (-)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):453-63. PubMed PMID: 7686633. 5: Prisco S, Cagnotto A, Talone D, De Blasi A, Mennini T, Esposito E. Tertatolol, a new beta-blocker, is a serotonin (5-hydroxytryptamine1A) receptor antagonist in rat brain. J Pharmacol Exp Ther. 1993 May;265(2):739-44. PubMed PMID: 8496820. 6: Calès P, Caillau H, Crambes O, Vinel JP, Desmorat H, Rocher I, Jung L, Urien S, Brouard R, Pascal JP. Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. J Hepatol. 1993 Aug;19(1):43-50. PubMed PMID: 7905493. 7: Branten AJ, Hilbrands LB, van Hamersvelt HW, Koene RA, Huysmans FT. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant. 1998 Feb;13(2):423-6. PubMed PMID: 9509456. 8: De Blasi A, Pittana PL, Fratelli M, Garattini S. Reduction of beta-adrenergic receptors can explain the lack of rebound effect after tertatolol withdrawal. Am J Hypertens. 1989 Nov;2(11 Pt 2):257S-260S. PubMed PMID: 2573373. 9: Shultz P, Raij L. Tertatolol: a beta-blocker with unique effects on human glomerular cell function. Cardiology. 1993;83 Suppl 1:51-6. PubMed PMID: 7903216. 10: Lave T, Efthymiopoulos C, Van Overloop B, Gairard A, Crambes O, Koffel JC, Jung L. Pharmacokinetics of the enantiomers of tertatolol in the rat after oral and intravenous administration. Xenobiotica. 1994 Jun;24(6):561-8. PubMed PMID: 7975722. 11: Mota JC, Carrageta MD, Felix S, Nunes AM, Jobbé-Duval M. Antihypertensive effects of tertatolol. A comparative study versus atenolol. Am J Hypertens. 1989 Nov;2(11 Pt 2):284S-288S. PubMed PMID: 2573377. 12: Verbeuren TJ, Zonnekeyn LL, Prost JF, Herman AG. Prejunctional beta-adrenoceptors in the isolated perfused rat kidney: a comparative study of the beta-blockers tertatolol and propranolol. Arch Int Pharmacodyn Ther. 1989 Mar-Apr;298:183-97. PubMed PMID: 2569296. 13: Smits JF, Zeegers HH, Struyker-Boudier HA. Stereospecificity of beta-adrenoceptor blockade and renal vasodilatation by tertatolol. Arch Int Pharmacodyn Ther. 1989 Mar-Apr;298:164-71. PubMed PMID: 2569294. 14: Saxena PR, Heiligers JP, Villalón CM, Ferrari MD. Effects of tertatolol, a beta-adrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. Eur J Pharmacol. 1992 Sep 10;220(1):79-86. PubMed PMID: 1358648. 15: Leeman M, Naeije R, Degaute JP, Brackman F, Prost JF. Acute central and renal haemodynamic responses to tertatolol and propranolol in patients with arterial hypertension following head injury. J Hypertens. 1986 Oct;4(5):581-7. PubMed PMID: 2878953. 16: Guillet C. Overview of novel renal properties of tertatolol. Cardiology. 1993;83 Suppl 1:64-9. Review. PubMed PMID: 7903218. 17: Gartside SE, Clifford EM, Cowen PJ, Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol. 1999 May;127(1):145-52. PubMed PMID: 10369467; PubMed Central PMCID: PMC1566011. 18: Laher MS. European experience with artex: the Tertatolol International Multicentre Study (TIMS). Cardiology. 1993;83 Suppl 1:25-31. PubMed PMID: 7903212. 19: Diehm C, Jacobsen O, Amendt K. The effects of tertatolol on lipid profile. Cardiology. 1993;83 Suppl 1:32-40. PubMed PMID: 7903213. 20: Naeije R, Degaute JP. Redistribution of cardiac output to the kidneys by tertatolol does not involve prostaglandins. Am J Hypertens. 1989 Nov;2(11 Pt 2):241S-244S. PubMed PMID: 2573371.